Susan H Adkins1, Kayla N Anderson2, Alyson B Goodman3, Evelyn Twentyman3, Melissa L Danielson2, Anne Kimball1, Eleanor S Click4, Jean Y Ko3, Mary E Evans5, David N Weissman6, Paul Melstrom3, Emily Kiernan7, Vikram Krishnasamy5, Dale A Rose8, Christopher M Jones5, Brian A King3, Sacha R Ellington3, Lori A Pollack3, Jennifer L Wiltz3. 1. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia. 3. National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Decatur, Georgia. 4. Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia. 5. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. 6. National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Atlanta, Georgia. 7. Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, Atlanta, Georgia. 8. National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
Importance: To date, limited information is available on the characteristics of adolescents with e-cigarette, or vaping, product use-associated lung injury (EVALI). Objective: To inform public health and clinical practice by describing differences in demographics, substance use behaviors, and clinical characteristics of EVALI among adolescents compared with adults. Design, Setting, and Participants: Surveillance data reported to the Centers for Disease Control and Prevention during the 2019 EVALI outbreak were used to calculate adjusted prevalence ratios (aPRs) with 95% CIs and to test differences between 360 hospitalized or deceased adolescents vs 859 young adults and 936 adults with EVALI (N = 2155). Main Outcomes and Measures: Demographics, substance use behaviors, and clinical characteristics. Results: Included in this cross-sectional study were 360 hospitalized or deceased adolescents (age range, 13-17 years; 67.9% male) vs 859 young adults (age range, 18-24 years; 72.4% male) and 936 adults (age range, 25-49 years; 65.6% male) with EVALI. Adolescents diagnosed as having EVALI reported using any nicotine-containing (62.4%), any tetrahydrocannabinol (THC)-containing (81.7%), and both (50.8%) types of e-cigarette or vaping products. Informal sources for obtaining nicotine-containing and THC-containing e-cigarette or vaping products were more commonly reported by adolescents (50.5% for nicotine and 96.5% for THC) than young adults (19.8% for nicotine [aPR, 2.49; 95% CI, 1.78-3.46] and 86.9% for THC [aPR, 1.11; 95% CI, 1.05-1.18]) or adults (24.3% for nicotine [aPR, 2.06; 95% CI, 1.49-2.84] and 75.1% for THC [aPR, 1.29; 95% CI, 1.19-1.40]). Mental, emotional, or behavioral disorders were commonly reported; a history of attention-deficit/hyperactivity disorder was almost 4 times more likely among adolescents (18.1%) than adults (4.9%) (aPR, 3.74; 95% CI, 1.92-7.26). A history of asthma was more likely to be reported among adolescents (43.6%) than adults (28.3%) (aPR, 1.53; 95% CI, 1.14-2.05). Gastrointestinal and constitutional symptoms were more common in adolescents (90.9% and 97.3%, respectively) than adults (75.3% and 94.5%, respectively) (aPR, 1.20; 95% CI, 1.13-1.28 and aPR, 1.03; 95% CI, 1.00-1.06, respectively). Because of missing data, percentages may not be able to be calculated from data provided. Conclusions and Relevance: Public health and clinical professionals should continue to provide information to adolescents about the association between EVALI and THC-containing e-cigarette or vaping product use, especially those products obtained through informal sources, and that the use of any e-cigarette or vaping product is unsafe. Compared with adults, it appears that adolescents with EVALI more frequently have a history of asthma and mental, emotional, or behavioral disorders, such as attention-deficit/hyperactivity disorder, and report nonspecific problems, including gastrointestinal and constitutional symptoms; therefore, obtaining a confidential substance use history that includes e-cigarette or vaping product use is recommended.
Importance: To date, limited information is available on the characteristics of adolescents with e-cigarette, or vaping, product use-associated lung injury (EVALI). Objective: To inform public health and clinical practice by describing differences in demographics, substance use behaviors, and clinical characteristics of EVALI among adolescents compared with adults. Design, Setting, and Participants: Surveillance data reported to the Centers for Disease Control and Prevention during the 2019 EVALI outbreak were used to calculate adjusted prevalence ratios (aPRs) with 95% CIs and to test differences between 360 hospitalized or deceased adolescents vs 859 young adults and 936 adults with EVALI (N = 2155). Main Outcomes and Measures: Demographics, substance use behaviors, and clinical characteristics. Results: Included in this cross-sectional study were 360 hospitalized or deceased adolescents (age range, 13-17 years; 67.9% male) vs 859 young adults (age range, 18-24 years; 72.4% male) and 936 adults (age range, 25-49 years; 65.6% male) with EVALI. Adolescents diagnosed as having EVALI reported using any nicotine-containing (62.4%), any tetrahydrocannabinol (THC)-containing (81.7%), and both (50.8%) types of e-cigarette or vaping products. Informal sources for obtaining nicotine-containing and THC-containing e-cigarette or vaping products were more commonly reported by adolescents (50.5% for nicotine and 96.5% for THC) than young adults (19.8% for nicotine [aPR, 2.49; 95% CI, 1.78-3.46] and 86.9% for THC [aPR, 1.11; 95% CI, 1.05-1.18]) or adults (24.3% for nicotine [aPR, 2.06; 95% CI, 1.49-2.84] and 75.1% for THC [aPR, 1.29; 95% CI, 1.19-1.40]). Mental, emotional, or behavioral disorders were commonly reported; a history of attention-deficit/hyperactivity disorder was almost 4 times more likely among adolescents (18.1%) than adults (4.9%) (aPR, 3.74; 95% CI, 1.92-7.26). A history of asthma was more likely to be reported among adolescents (43.6%) than adults (28.3%) (aPR, 1.53; 95% CI, 1.14-2.05). Gastrointestinal and constitutional symptoms were more common in adolescents (90.9% and 97.3%, respectively) than adults (75.3% and 94.5%, respectively) (aPR, 1.20; 95% CI, 1.13-1.28 and aPR, 1.03; 95% CI, 1.00-1.06, respectively). Because of missing data, percentages may not be able to be calculated from data provided. Conclusions and Relevance: Public health and clinical professionals should continue to provide information to adolescents about the association between EVALI and THC-containing e-cigarette or vaping product use, especially those products obtained through informal sources, and that the use of any e-cigarette or vaping product is unsafe. Compared with adults, it appears that adolescents with EVALI more frequently have a history of asthma and mental, emotional, or behavioral disorders, such as attention-deficit/hyperactivity disorder, and report nonspecific problems, including gastrointestinal and constitutional symptoms; therefore, obtaining a confidential substance use history that includes e-cigarette or vaping product use is recommended.
Authors: Denitza P Blagev; Dixie Harris; Angela C Dunn; David W Guidry; Colin K Grissom; Michael J Lanspa Journal: Lancet Date: 2019-11-08 Impact factor: 79.321
Authors: Isaac Ghinai; Ian W Pray; Livia Navon; Kevin O'Laughlin; Lori Saathoff-Huber; Brooke Hoots; Anne Kimball; Mark W Tenforde; Jennifer R Chevinsky; Mark Layer; Ngozi Ezike; Jonathan Meiman; Jennifer E Layden Journal: MMWR Morb Mortal Wkly Rep Date: 2019-10-04 Impact factor: 17.586
Authors: Erin D Moritz; Lauren B Zapata; Akaki Lekiachvili; Emily Glidden; Francis B Annor; Angela K Werner; Emily N Ussery; Michelle M Hughes; Anne Kimball; Carla L DeSisto; Brandon Kenemer; Mays Shamout; Macarena C Garcia; Sarah Reagan-Steiner; Emily E Petersen; Emily H Koumans; Matthew D Ritchey; Brian A King; Christopher M Jones; Peter A Briss; Lisa Delaney; Anita Patel; Kara D Polen; Katie Sives; Dana Meaney-Delman; Kevin Chatham-Stephens Journal: MMWR Morb Mortal Wkly Rep Date: 2019-11-01 Impact factor: 17.586
Authors: Andrea C Villanti; S Elisha LePine; Julia C West; Tess Boley Cruz; Elise M Stevens; Haley J Tetreault; Jennifer B Unger; Olivia A Wackowski; Darren Mays Journal: Addict Behav Date: 2020-12-11 Impact factor: 3.913
Authors: Melissa B Harrell; Baojiang Chen; Stephanie L Clendennen; Aslesha Sumbe; Kathleen R Case; Anna V Wilkinson; Alexandra Loukas; Cheryl L Perry Journal: Prev Med Date: 2021-06-01 Impact factor: 4.637
Authors: Lynnette Nathalie Lyzwinski; John A Naslund; Christopher J Miller; Mark J Eisenberg Journal: NPJ Prim Care Respir Med Date: 2022-04-11 Impact factor: 3.289